<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37814605</PMID><DateRevised><Year>2023</Year><Month>10</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1179-1535</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Hepatic medicine : evidence and research</Title><ISOAbbreviation>Hepat Med</ISOAbbreviation></Journal><ArticleTitle>Clinical and Histopathological Discoveries in Patients with Hepatic Injury and Cholangiopathy Who Have Died of COVID-19: Insights and Opportunities for Intervention.</ArticleTitle><Pagination><StartPage>151</StartPage><EndPage>164</EndPage><MedlinePgn>151-164</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/HMER.S385133</ELocationID><Abstract><AbstractText>The COVID-19 pandemic has had a profound impact on global health, necessitating a comprehensive understanding of its diverse manifestations. Cholangiopathy, a condition characterized by biliary dysfunction, has emerged as a significant complication in COVID-19 patients. In this review, we report the epidemiology of COVID-19, describe the hepatotropism of SARS-CoV-2, and present the histopathology of acute liver injury (ALI) in COVID-19. Additionally, we explore the relationship between pre-existing chronic liver disease and COVID-19, shedding light on the increased susceptibility of these individuals to develop cholangiopathy. Through an in-depth analysis of cholangiopathy in COVID-19 patients, we elucidate its clinical manifestations, diagnostic criteria, and underlying pathogenesis involving inflammation, immune dysregulation, and vascular changes. Furthermore, we provide a summary of studies investigating post-COVID-19 cholangiopathy, highlighting the long-term effects and potential management strategies for this condition, and discussing opportunities for intervention, including therapeutic targets, diagnostic advancements, supportive care, and future research needs.</AbstractText><CopyrightInformation>&#xa9; 2023 Lim and Njei.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Joseph K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Yale Liver Center and Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Njei</LastName><ForeName>Basile</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Yale Liver Center and Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Hepat Med</MedlineTA><NlmUniqueID>101544801</NlmUniqueID><ISSNLinking>1179-1535</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">cholangiopathy</Keyword><Keyword MajorTopicYN="N">histopathology</Keyword><Keyword MajorTopicYN="N">interventions</Keyword><Keyword MajorTopicYN="N">long-COVID-19</Keyword></KeywordList><CoiStatement>Dr Joseph K Lim reports grants from Intercept, Viking, Novo Nordisk, Gilead, Pfizer, and Inventiva, outside the submitted work. The authors report no other conflicts of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>10</Day><Hour>3</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37814605</ArticleId><ArticleId IdType="pmc">PMC10560482</ArticleId><ArticleId IdType="doi">10.2147/HMER.S385133</ArticleId><ArticleId IdType="pii">385133</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alenazy AES, Alabdulwahab K, Alabdulwahab F, Alanazi SIS. Cutaneous manifestations and types of skin affection associated with COVID-19 infection: a simple review. Arch Pharm Pract. 2022;13(2):95.</Citation></Reference><Reference><Citation>Lala A, Johnson KW, Januzzi JL, et al. Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. J Am Coll Cardiol. 2020;76(5):533&#x2013;546. doi:10.1016/j.jacc.2020.06.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.06.007</ArticleId><ArticleId IdType="pmc">PMC7279721</ArticleId><ArticleId IdType="pubmed">32517963</ArticleId></ArticleIdList></Reference><Reference><Citation>Elrobaa IH, New KJ. COVID-19: pulmonary and extra pulmonary manifestations. Front Public Health. 2021;9:711616. doi:10.3389/fpubh.2021.711616</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2021.711616</ArticleId><ArticleId IdType="pmc">PMC8505777</ArticleId><ArticleId IdType="pubmed">34650947</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanif FM, Majid Z, Ahmed S, Luck NH, Mubarak M. Hepatic manifestations of coronavirus disease 2019 infection: clinical and laboratory perspective. World J Virol. 2022;11(6):453. doi:10.5501/wjv.v11.i6.453</Citation><ArticleIdList><ArticleId IdType="doi">10.5501/wjv.v11.i6.453</ArticleId><ArticleId IdType="pmc">PMC9724207</ArticleId><ArticleId IdType="pubmed">36483109</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee A, Wein AN, Doyle MBM, Chapman WC. Liver transplantation for post-COVID-19 sclerosing cholangitis. BMJ Case Rep CP. 2021;14(8):e244168. doi:10.1136/bcr-2021-244168</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2021-244168</ArticleId><ArticleId IdType="pmc">PMC8395362</ArticleId><ArticleId IdType="pubmed">34446515</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Y, Liu Y, Zhao Q, et al. Liver injury in patients with COVID-19: a Retrospective Study. Int J Med Sci. 2023;20(3):385. doi:10.7150/ijms.81214</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.81214</ArticleId><ArticleId IdType="pmc">PMC9969505</ArticleId><ArticleId IdType="pubmed">36860673</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med Virol. 2020;92(4):401&#x2013;402. doi:10.1002/jmv.25678</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25678</ArticleId><ArticleId IdType="pmc">PMC7166628</ArticleId><ArticleId IdType="pubmed">31950516</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. WHO Coronavirus (COVID-19) Dashboard; 2022. Available from: https://covid19.who.int/. Accessed September
29, 2023.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA: US Department of Health and Human Services, CDC; 2022. Available from: https://covid.cdc.gov/covid-data-tracker. Accessed September
29, 2023.</Citation></Reference><Reference><Citation>Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369. doi:10.1136/bmj.m1966</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1966</ArticleId><ArticleId IdType="pmc">PMC7243801</ArticleId><ArticleId IdType="pubmed">32444366</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganatra S, Hammond SP, Nohria A. The Novel Coronavirus Disease (COVID-19) Threat for Patients with Cardiovascular Disease and Cancer. Vol. 2. Washington DC: American College of Cardiology Foundation; 2020:350&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7151392</ArticleId><ArticleId IdType="pubmed">32292919</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnett ML, Grabowski DC. Nursing homes are ground zero for COVID-19 pandemic. Paper presented at: JAMA Health Forum; 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">36218601</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271&#x2013;280.e278. doi:10.1016/j.cell.2020.02.052</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Menachery VD, Dinnon KH, Yount BL, et al. Trypsin treatment unlocks barrier for zoonotic bat coronavirus infection. J Virol. 2020;94(5). doi:10.1128/JVI.01774-19</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01774-19</ArticleId><ArticleId IdType="pmc">PMC7022341</ArticleId><ArticleId IdType="pubmed">31801868</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons G, Gosalia DN, Rennekamp AJ, Reeves JD, Diamond SL, Bates P Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci U S A. 2005;102(33):11876&#x2013;11881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1188015</ArticleId><ArticleId IdType="pubmed">16081529</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022;23(1):3&#x2013;20. doi:10.1038/s41580-021-00418-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00418-x</ArticleId><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei C, Wan L, Yan Q, et al. HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry. Nat Metabol. 2020;2(12):1391&#x2013;1400. doi:10.1038/s42255-020-00324-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42255-020-00324-0</ArticleId><ArticleId IdType="pubmed">33244168</ArticleId></ArticleIdList></Reference><Reference><Citation>Chidambaram V, Shanmugavel Geetha H, Kumar A, et al. Association of lipid levels with COVID-19 infection, disease severity and mortality: a systematic review and meta-analysis. Front Cardiovasc Med. 2022;9:862999. doi:10.3389/fcvm.2022.862999</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.862999</ArticleId><ArticleId IdType="pmc">PMC8988060</ArticleId><ArticleId IdType="pubmed">35402531</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D, Ding X, Xie M, Tian D, Xia L. COVID-19-associated liver injury: from bedside to bench. J Gastroenterol. 2021;56(3):218&#x2013;230. doi:10.1007/s00535-021-01760-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00535-021-01760-9</ArticleId><ArticleId IdType="pmc">PMC7849620</ArticleId><ArticleId IdType="pubmed">33527211</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Xiao S-Y. Hepatic involvement in COVID-19 patients: pathology, pathogenesis, and clinical implications. J Med Virol. 2020;92(9):1491&#x2013;1494. doi:10.1002/jmv.25973</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25973</ArticleId><ArticleId IdType="pubmed">32369204</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge J, Pletcher MJ, Lai JC, Harper JR, Chute CG, Haendel MA. Outcomes of SARS-CoV-2 infection in patients with chronic liver disease and cirrhosis: a National COVID Cohort Collaborative Study. Gastroenterology. 2021;161(5):1487&#x2013;1501.e1485. doi:10.1053/j.gastro.2021.07.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2021.07.010</ArticleId><ArticleId IdType="pmc">PMC8286237</ArticleId><ArticleId IdType="pubmed">34284037</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerussi A, Rigamonti C, Elia C, et al. Coronavirus disease 2019 in autoimmune hepatitis: a lesson from immunosuppressed patients. Hepatol Commun. 2020;4(9):1257&#x2013;1262. doi:10.1002/hep4.1557</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep4.1557</ArticleId><ArticleId IdType="pmc">PMC7300554</ArticleId><ArticleId IdType="pubmed">32838102</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D, Long Y, Huang P, et al. Clinical characteristics of 80 patients with COVID-19 in Zhuzhou City. J Chin J Infect Control. 2020;19(03):227&#x2013;233.</Citation></Reference><Reference><Citation>Chu H, Chan JF, Yuen TT, et al. Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study. Lancet Microbe. 2020;1(1):e14&#x2013;e23. doi:10.1016/S2666-5247(20)30004-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(20)30004-5</ArticleId><ArticleId IdType="pmc">PMC7173822</ArticleId><ArticleId IdType="pubmed">32835326</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji D, Qin E, Xu J, et al. Non-alcoholic fatty liver diseases in patients with COVID-19: a retrospective study. J Hepatol. 2020;73(2):451&#x2013;453. doi:10.1016/j.jhep.2020.03.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2020.03.044</ArticleId><ArticleId IdType="pmc">PMC7141624</ArticleId><ArticleId IdType="pubmed">32278005</ArticleId></ArticleIdList></Reference><Reference><Citation>Koliaki C, Szendroedi J, Kaul K, et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab. 2015;21(5):739&#x2013;746. doi:10.1016/j.cmet.2015.04.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2015.04.004</ArticleId><ArticleId IdType="pubmed">25955209</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo AD, Schneeweiss-Gleixner M, Bakail M, Dixon ED, Lax SF, Trauner M. Pathophysiological mechanisms of liver injury in COVID-19. Liver Int. 2021;41(1):20&#x2013;32. doi:10.1111/liv.14730</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/liv.14730</ArticleId><ArticleId IdType="pmc">PMC7753756</ArticleId><ArticleId IdType="pubmed">33190346</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangash MN, Patel JM, Parekh D, et al. SARS-CoV-2: is the liver merely a bystander to severe disease? J Hepatol. 2020;73(4):995&#x2013;996. doi:10.1016/j.jhep.2020.05.035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2020.05.035</ArticleId><ArticleId IdType="pmc">PMC7265856</ArticleId><ArticleId IdType="pubmed">32502510</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryce C, Grimes Z, Pujadas E, et al. Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience. Mod Pathol. 2021;34(8):1456&#x2013;1467. doi:10.1038/s41379-021-00793-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41379-021-00793-y</ArticleId><ArticleId IdType="pmc">PMC8015313</ArticleId><ArticleId IdType="pubmed">33795830</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Zhou Y, Wang DW. SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz. 2020;45(3):230&#x2013;232. doi:10.1007/s00059-020-04909-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00059-020-04909-z</ArticleId><ArticleId IdType="pmc">PMC7080076</ArticleId><ArticleId IdType="pubmed">32140732</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen LY, Chu HK, Bai T, et al. Liver damage at admission is an independent prognostic factor for COVID-19. J Dig Dis. 2020;21(9):512&#x2013;518. doi:10.1111/1751-2980.12925</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1751-2980.12925</ArticleId><ArticleId IdType="pubmed">32713118</ArticleId></ArticleIdList></Reference><Reference><Citation>Khateri S, Mohammadi H, Khateri R, Moradi Y. The prevalence of underlying diseases and comorbidities in COVID-19 patients; an updated systematic review and meta-analysis. Arch Acad Emerg Med. 2020;8(1):e72&#x2013;e72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7588001</ArticleId><ArticleId IdType="pubmed">33134968</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajaj JS, Garcia-Tsao G, Biggins SW, et al. Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. Gut. 2021;70(3):531. doi:10.1136/gutjnl-2020-322118</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-322118</ArticleId><ArticleId IdType="pmc">PMC7371484</ArticleId><ArticleId IdType="pubmed">32660964</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni AV, Kumar P, Tevethia HV, et al. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. Aliment Pharmacol Ther. 2020;52(4):584&#x2013;599. doi:10.1111/apt.15916</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15916</ArticleId><ArticleId IdType="pmc">PMC7361465</ArticleId><ArticleId IdType="pubmed">32638436</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar MP, Mishra S, Jha DK, et al. Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis. Hepatol Int. 2020;14(5):711&#x2013;722. doi:10.1007/s12072-020-10071-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12072-020-10071-9</ArticleId><ArticleId IdType="pmc">PMC7335221</ArticleId><ArticleId IdType="pubmed">32623633</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar P, Sharma M, Kulkarni A, Rao PN. Pathogenesis of liver injury in Coronavirus Disease 2019. J Clin Exp Hepatol. 2020;10(6):641&#x2013;642. doi:10.1016/j.jceh.2020.05.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jceh.2020.05.006</ArticleId><ArticleId IdType="pmc">PMC7237376</ArticleId><ArticleId IdType="pubmed">32837092</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreira JLS, Barbosa SMB, Gon&#xe7;alves J&#xfa;nior J. Pathophysiology and molecular mechanisms of liver injury in severe forms of COVID-19: an integrative review. Clin Res Hepatol Gastroenterol. 2021;45(6):101752. doi:10.1016/j.clinre.2021.101752</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinre.2021.101752</ArticleId><ArticleId IdType="pmc">PMC8299216</ArticleId><ArticleId IdType="pubmed">34303828</ArticleId></ArticleIdList></Reference><Reference><Citation>Phipps MM, Barraza LH, LaSota ED, et al. Acute liver injury in COVID-19: prevalence and association with clinical outcomes in a large US cohort. Hepatology. 2020;72(3):807&#x2013;817. doi:10.1002/hep.31404</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.31404</ArticleId><ArticleId IdType="pmc">PMC7300739</ArticleId><ArticleId IdType="pubmed">32473607</ArticleId></ArticleIdList></Reference><Reference><Citation>Shokri Afra H, Amiri-Dashatan N, Ghorbani F, Maleki I, Rezaei-Tavirani M. Positive association between severity of COVID-19 infection and liver damage: a systematic review and meta-analysis. Gastroenterol Hepatol Bed Bench. 2020;13(4):292&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7682972</ArticleId><ArticleId IdType="pubmed">33244371</ArticleId></ArticleIdList></Reference><Reference><Citation>Spearman CW, Aghemo A, Valenti L, Sonderup MW. COVID-19 and the liver: a 2021 update. Liver Int. 2021;41(9):1988&#x2013;1998. doi:10.1111/liv.14984</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/liv.14984</ArticleId><ArticleId IdType="pubmed">34152690</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Li H, Guo X, et al. Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis. Hepatol Int. 2020;14(5):621&#x2013;637. doi:10.1007/s12072-020-10074-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12072-020-10074-6</ArticleId><ArticleId IdType="pmc">PMC7380163</ArticleId><ArticleId IdType="pubmed">32710250</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420&#x2013;422. doi:10.1016/S2213-2600(20)30076-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30076-X</ArticleId><ArticleId IdType="pmc">PMC7164771</ArticleId><ArticleId IdType="pubmed">32085846</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q. Liver impairment in COVID-19 patients: a retrospective analysis of 115 cases from a single centre in Wuhan city, China. Liver Int. 2020;40(9):2095&#x2013;2103. doi:10.1111/liv.14455</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/liv.14455</ArticleId><ArticleId IdType="pubmed">32239796</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloom PP, Meyerowitz EA, Reinus Z, et al. Liver Biochemistries in Hospitalized Patients With COVID-19. Hepatology. 2021;73(3):890&#x2013;900. doi:10.1002/hep.31326</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.31326</ArticleId><ArticleId IdType="pubmed">32415860</ArticleId></ArticleIdList></Reference><Reference><Citation>Du M, Yang S, Liu M, Liu J. COVID-19 and liver dysfunction: epidemiology, association and potential mechanisms. Clin Res Hepatol Gastroenterol. 2022;46(2):101793. doi:10.1016/j.clinre.2021.101793</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinre.2021.101793</ArticleId><ArticleId IdType="pmc">PMC8380064</ArticleId><ArticleId IdType="pubmed">34428501</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng G, Zheng KI, Yan QQ, et al. COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies. J Clin Transl Hepatol. 2020;8(1):18&#x2013;24. doi:10.14218/JCTH.2020.00018</Citation><ArticleIdList><ArticleId IdType="doi">10.14218/JCTH.2020.00018</ArticleId><ArticleId IdType="pmc">PMC7132016</ArticleId><ArticleId IdType="pubmed">32274342</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabrielli M, Franza L, Esperide A, et al. Liver injury in patients hospitalized for COVID-19: possible role of therapy. Vaccines. 2022;10(2):192. doi:10.3390/vaccines10020192</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10020192</ArticleId><ArticleId IdType="pmc">PMC8880796</ArticleId><ArticleId IdType="pubmed">35214651</ArticleId></ArticleIdList></Reference><Reference><Citation>Hundt MA, Deng Y, Ciarleglio MM, Nathanson MH, Lim JK. Abnormal liver tests in COVID-19: a retrospective observational cohort study of 1827 patients in a major US hospital network. Hepatology. 2020;72(4):1169&#x2013;1176. doi:10.1002/hep.31487</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.31487</ArticleId><ArticleId IdType="pmc">PMC9258788</ArticleId><ArticleId IdType="pubmed">32725890</ArticleId></ArticleIdList></Reference><Reference><Citation>Jothimani D, Venugopal R, Abedin MF, Kaliamoorthy I, Rela M. COVID-19 and the liver. J Hepatol. 2020;73(5):1231&#x2013;1240. doi:10.1016/j.jhep.2020.06.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2020.06.006</ArticleId><ArticleId IdType="pmc">PMC7295524</ArticleId><ArticleId IdType="pubmed">32553666</ArticleId></ArticleIdList></Reference><Reference><Citation>Marjot T, Webb GJ, Barritt AS, et al. COVID-19 and liver disease: mechanistic and clinical perspectives. Nat Rev Gastroenterol Hepatol. 2021;18(5):348&#x2013;364. doi:10.1038/s41575-021-00426-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-021-00426-4</ArticleId><ArticleId IdType="pmc">PMC7945972</ArticleId><ArticleId IdType="pubmed">33692570</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon AM, Barritt A. Elevated liver enzymes in patients with COVID-19: look, but not too hard. Dig Dis Sci. 2021;66(6):1767&#x2013;1769. doi:10.1007/s10620-020-06585-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-020-06585-9</ArticleId><ArticleId IdType="pmc">PMC7462733</ArticleId><ArticleId IdType="pubmed">32875529</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarin SK, Choudhury A, Lau GK, et al. Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; the APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study). Hepatol Int. 2020;14(5):690&#x2013;700. doi:10.1007/s12072-020-10072-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12072-020-10072-8</ArticleId><ArticleId IdType="pmc">PMC7334898</ArticleId><ArticleId IdType="pubmed">32623632</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaefer EAK, Arvind A, Bloom PP, Chung RT. Interrelationship between coronavirus infection and liver disease. Clin Liver Dis. 2020;15(5):175&#x2013;180. doi:10.1002/cld.967</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cld.967</ArticleId><ArticleId IdType="pmc">PMC7242011</ArticleId><ArticleId IdType="pubmed">32489653</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, Khan A. Clinical characteristics and outcomes of coronavirus disease 2019 among patients with preexisting liver disease in the United States: a Multicenter Research Network Study. Gastroenterology. 2020;159(2):768&#x2013;771.e763. doi:10.1053/j.gastro.2020.04.064</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.04.064</ArticleId><ArticleId IdType="pmc">PMC7196546</ArticleId><ArticleId IdType="pubmed">32376408</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang H, Zhou L, Li X, et al. Drug-induced liver injury associated with lopinavir-ritonavir in patients with COVID-19: a disproportionality analysis of U.S. food and drug administration adverse event reporting system (FAERS) data. Int J Clin Pharm. 2021;43(4):1116&#x2013;1122. doi:10.1007/s11096-021-01311-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11096-021-01311-5</ArticleId><ArticleId IdType="pmc">PMC8323539</ArticleId><ArticleId IdType="pubmed">34328585</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan J, Wang X, Su S, et al. Digestive symptoms and liver injury in patients with coronavirus disease 2019 (COVID-19): a systematic review with meta-analysis. JGH Open. 2020;4(6):1047&#x2013;1058. doi:10.1002/jgh3.12428</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jgh3.12428</ArticleId><ArticleId IdType="pmc">PMC7731824</ArticleId><ArticleId IdType="pubmed">33319036</ArticleId></ArticleIdList></Reference><Reference><Citation>Z-h W, Yang D. A meta-analysis of the impact of COVID-19 on liver dysfunction. Eur J Med Res. 2020;25(1):54. doi:10.1186/s40001-020-00454-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40001-020-00454-x</ArticleId><ArticleId IdType="pmc">PMC7609835</ArticleId><ArticleId IdType="pubmed">33148326</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav DK, Singh A, Zhang Q, et al. Involvement of liver in COVID-19: systematic review and meta-analysis. Gut. 2021;70(4):807&#x2013;809. doi:10.1136/gutjnl-2020-322072</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-322072</ArticleId><ArticleId IdType="pmc">PMC7948176</ArticleId><ArticleId IdType="pubmed">32669289</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie X, Qian L, Sun R, et al. Multi-organ proteomic landscape of COVID-19 autopsies. Cell. 2021;184(3):775&#x2013;791.e714. doi:10.1016/j.cell.2021.01.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.01.004</ArticleId><ArticleId IdType="pmc">PMC7794601</ArticleId><ArticleId IdType="pubmed">33503446</ArticleId></ArticleIdList></Reference><Reference><Citation>Chornenkyy Y, Mejia-Bautista M, Brucal M, et al. Liver pathology and SARS-CoV-2 detection in formalin-fixed tissue of patients with COVID-19. Am J Clin Pathol. 2021;155(6):802&#x2013;814. doi:10.1093/ajcp/aqab009</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcp/aqab009</ArticleId><ArticleId IdType="pmc">PMC8135761</ArticleId><ArticleId IdType="pubmed">33914058</ArticleId></ArticleIdList></Reference><Reference><Citation>Kushner T, Cafardi J. Chronic liver disease and COVID-19: alcohol use disorder/alcohol-associated liver disease, nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, autoimmune liver disease, and compensated cirrhosis. Clin Liver Dis. 2020;15(5):195&#x2013;199. doi:10.1002/cld.974</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cld.974</ArticleId><ArticleId IdType="pmc">PMC7280613</ArticleId><ArticleId IdType="pubmed">32537135</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagana SM, Kudose S, Iuga AC, et al. Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data. Mod Pathol. 2020;33(11):2147&#x2013;2155. doi:10.1038/s41379-020-00649-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41379-020-00649-x</ArticleId><ArticleId IdType="pmc">PMC7424245</ArticleId><ArticleId IdType="pubmed">32792598</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xed;az LA, Idalsoaga F, Cannistra M, et al. High prevalence of hepatic steatosis and vascular thrombosis in COVID-19: a systematic review and meta-analysis of autopsy data. World J Gastroenterol. 2020;26(48):7693&#x2013;7706. doi:10.3748/wjg.v26.i48.7693</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v26.i48.7693</ArticleId><ArticleId IdType="pmc">PMC7789052</ArticleId><ArticleId IdType="pubmed">33505145</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachdeva S, Khandait H, Kopel J, Aloysius MM, Desai R, Goyal H. NAFLD and COVID-19: a pooled analysis. SN Comprehen Clin Med. 2020;2(12):2726&#x2013;2729. doi:10.1007/s42399-020-00631-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s42399-020-00631-3</ArticleId><ArticleId IdType="pmc">PMC7646222</ArticleId><ArticleId IdType="pubmed">33173850</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou YJ, Zheng KI, Wang XB, et al. Metabolic-associated fatty liver disease is associated with severity of COVID-19. Liver Int. 2020;40(9):2160&#x2013;2163. doi:10.1111/liv.14575</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/liv.14575</ArticleId><ArticleId IdType="pmc">PMC7361853</ArticleId><ArticleId IdType="pubmed">32573883</ArticleId></ArticleIdList></Reference><Reference><Citation>Leo M, Galante A, Pagnamenta A, et al. Hepatocellular liver injury in hospitalized patients affected by COVID-19: presence of different risk factors at different time points. Dig Liver Dis. 2022;54(5):565&#x2013;571. doi:10.1016/j.dld.2021.12.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2021.12.014</ArticleId><ArticleId IdType="pmc">PMC8710398</ArticleId><ArticleId IdType="pubmed">35093272</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajaj JS. Altered microbiota in cirrhosis and its relationship to the development of infection. Clin Liver Dis. 2019;14(3):107&#x2013;111. doi:10.1002/cld.827</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cld.827</ArticleId><ArticleId IdType="pmc">PMC6784803</ArticleId><ArticleId IdType="pubmed">31632660</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeoh YK, Zuo T, Lui GC-Y, et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021;70(4):698. doi:10.1136/gutjnl-2020-323020</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-323020</ArticleId><ArticleId IdType="pmc">PMC7804842</ArticleId><ArticleId IdType="pubmed">33431578</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovalic AJ, Satapathy SK, Thuluvath PJ. Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis. Hepatol Int. 2020;14(5):612&#x2013;620. doi:10.1007/s12072-020-10078-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12072-020-10078-2</ArticleId><ArticleId IdType="pmc">PMC7386238</ArticleId><ArticleId IdType="pubmed">32725453</ArticleId></ArticleIdList></Reference><Reference><Citation>Marjot T, Moon AM, Cook JA, et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study. J Hepatol. 2021;74(3):567&#x2013;577. doi:10.1016/j.jhep.2020.09.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2020.09.024</ArticleId><ArticleId IdType="pmc">PMC7536538</ArticleId><ArticleId IdType="pubmed">33035628</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430&#x2013;436. doi:10.1038/s41586-020-2521-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2521-4</ArticleId><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>Butt AA, Yan P. Rates and characteristics of SARS-CoV-2 infection in persons with hepatitis C virus infection. Liver Int. 2021;41(1):76&#x2013;80. doi:10.1111/liv.14681</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/liv.14681</ArticleId><ArticleId IdType="pmc">PMC7537048</ArticleId><ArticleId IdType="pubmed">33006798</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W-J, Z-Y N, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708&#x2013;1720. doi:10.1056/NEJMoa2002032</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>He Q, Zhang G, Gu Y, et al. Clinical characteristics of COVID-19 patients with pre-existing hepatitis b virus infection: a multicenter report. Am J Gastroenterol. 2021;116(2):420&#x2013;421. doi:10.14309/ajg.0000000000000924</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000000924</ArticleId><ArticleId IdType="pmc">PMC7505029</ArticleId><ArticleId IdType="pubmed">32925195</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D, Adeniji N, Latt N, et al. Predictors of outcomes of COVID-19 in patients with chronic liver disease: US Multi-center Study. Clin Gastroenterol Hepatol. 2021;19(7):1469&#x2013;1479.e1419. doi:10.1016/j.cgh.2020.09.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2020.09.027</ArticleId><ArticleId IdType="pmc">PMC7497795</ArticleId><ArticleId IdType="pubmed">32950749</ArticleId></ArticleIdList></Reference><Reference><Citation>Fix OK, Blumberg EA, Chang KM, et al. American Association for the Study of liver diseases expert panel consensus statement: vaccines to prevent Coronavirus Disease 2019 infection in patients with liver disease. Hepatology. 2021;74(2):1049&#x2013;1064. doi:10.1002/hep.31751</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.31751</ArticleId><ArticleId IdType="pmc">PMC8014184</ArticleId><ArticleId IdType="pubmed">33577086</ArticleId></ArticleIdList></Reference><Reference><Citation>Fix OK, Hameed B, Fontana RJ, et al. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD Expert Panel Consensus Statement. Hepatology. 2020;72(1):287&#x2013;304. doi:10.1002/hep.31281</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.31281</ArticleId><ArticleId IdType="pmc">PMC7262242</ArticleId><ArticleId IdType="pubmed">32298473</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons B, Wentzel H, Mobarak S, et al. Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis. J Antimicrob Chemother. 2021;76(2):286&#x2013;291. doi:10.1093/jac/dkaa418</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkaa418</ArticleId><ArticleId IdType="pmc">PMC7665526</ArticleId><ArticleId IdType="pubmed">33063117</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashemi N, Viveiros K, Redd WD, et al. Impact of chronic liver disease on outcomes of hospitalized patients with COVID-19: a multicentre United States experience. Liver Int. 2020;40(10):2515&#x2013;2521. doi:10.1111/liv.14583</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/liv.14583</ArticleId><ArticleId IdType="pmc">PMC7361757</ArticleId><ArticleId IdType="pubmed">32585065</ArticleId></ArticleIdList></Reference><Reference><Citation>Shelton JF, Shastri AJ, Ye C, et al. Trans-ancestry analysis reveals genetic and nongenetic associations with COVID-19 susceptibility and severity. Nat Genet. 2021;53(6):801&#x2013;808. doi:10.1038/s41588-021-00854-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-021-00854-7</ArticleId><ArticleId IdType="pubmed">33888907</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Antiga L. Coronaviruses and immunosuppressed patients: the facts during the third epidemic. Liver Transplant. 2020;26(6):832&#x2013;834. doi:10.1002/lt.25756</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lt.25756</ArticleId><ArticleId IdType="pubmed">32196933</ArticleId></ArticleIdList></Reference><Reference><Citation>Marjot T, Buescher G, Sebode M, et al. SARS-CoV-2 infection in patients with autoimmune hepatitis. J Hepatol. 2021;74(6):1335&#x2013;1343. doi:10.1016/j.jhep.2021.01.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2021.01.021</ArticleId><ArticleId IdType="pmc">PMC7835076</ArticleId><ArticleId IdType="pubmed">33508378</ArticleId></ArticleIdList></Reference><Reference><Citation>Belli LS, Fondevila C, Cortesi PA, et al. Protective role of tacrolimus, deleterious role of age and comorbidities in liver transplant recipients with Covid-19: results from the ELITA/ELTR Multi-center European Study. Gastroenterology. 2021;160(4):1151&#x2013;1163.e1153. doi:10.1053/j.gastro.2020.11.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.11.045</ArticleId><ArticleId IdType="pmc">PMC7724463</ArticleId><ArticleId IdType="pubmed">33307029</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonhardt S, J&#xfc;rgensen C, Frohme J, et al. Hepatobiliary long-term consequences of COVID-19: dramatically increased rate of secondary sclerosing cholangitis in critically ill COVID-19 patients. Hepatol Int;2023. 1&#x2013;16. doi:10.1007/s12072-023-10521-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12072-023-10521-0</ArticleId><ArticleId IdType="pmc">PMC10148013</ArticleId><ArticleId IdType="pubmed">37119516</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadlapati S, Jarrett SA, Baik D, Chaaya A. COVID-19 related biliary injury: a review of recent literature. World J Gastroenterol. 2023;29(14):2127. doi:10.3748/wjg.v29.i14.2127</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v29.i14.2127</ArticleId><ArticleId IdType="pmc">PMC10130971</ArticleId><ArticleId IdType="pubmed">37122603</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth NC, Kim A, Vitkovski T, et al. Post-COVID-19 Cholangiopathy: a Novel Entity. Am J Gastroenterol. 2021;116(5):1077&#x2013;1082. doi:10.14309/ajg.0000000000001154</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000001154</ArticleId><ArticleId IdType="pubmed">33464757</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas M, Rodr&#xed;guez Y, Zapata E, Hern&#xe1;ndez JC, Anaya J-M. Cholangiopathy as part of post-COVID syndrome. J Transl Autoimmun. 2021;4:100116. doi:10.1016/j.jtauto.2021.100116</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100116</ArticleId><ArticleId IdType="pmc">PMC8406516</ArticleId><ArticleId IdType="pubmed">34485887</ArticleId></ArticleIdList></Reference><Reference><Citation>Durazo FA, Nicholas AA, Mahaffey JJ, et al. Post&#x2013;Covid-19 cholangiopathy&#x2014;a new indication for liver transplantation: a case report. Paper presented at: Transplantation proceedings; 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7953456</ArticleId><ArticleId IdType="pubmed">33846012</ArticleId></ArticleIdList></Reference><Reference><Citation>Linneweber L, Mann AB, Denk G, Kraft E, Weber S. Cholangiopathy in early rehabilitation after intensive care treatment of patients with COVID-19. Off J Am College Gastroenterol. 2022;117(1):197&#x2013;198. doi:10.14309/ajg.0000000000001511</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000001511</ArticleId><ArticleId IdType="pubmed">34585676</ArticleId></ArticleIdList></Reference><Reference><Citation>Tafreshi S, Whiteside I, Levine I, D&#x2019;Agostino C. A case of secondary sclerosing cholangitis due to COVID-19. Clin Imaging. 2021;80:239&#x2013;242. doi:10.1016/j.clinimag.2021.07.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinimag.2021.07.017</ArticleId><ArticleId IdType="pmc">PMC8314797</ArticleId><ArticleId IdType="pubmed">34364072</ArticleId></ArticleIdList></Reference><Reference><Citation>Machado MCC, Kalil Filho R, El Bacha IAH, et al. Post-COVID-19 secondary sclerosing cholangitis: a rare but severe condition with no treatment besides liver transplantation. Am J Case Rep. 2022;23:e936250&#x2013;e936251. doi:10.12659/AJCR.936250</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/AJCR.936250</ArticleId><ArticleId IdType="pmc">PMC9394546</ArticleId><ArticleId IdType="pubmed">35978523</ArticleId></ArticleIdList></Reference><Reference><Citation>Wongtanasarasin W. Cholestatic liver injury: a rare but fatal complication during and after COVID-19 infection. World J Virol. 2022;11(6):435. doi:10.5501/wjv.v11.i6.435</Citation><ArticleIdList><ArticleId IdType="doi">10.5501/wjv.v11.i6.435</ArticleId><ArticleId IdType="pmc">PMC9724201</ArticleId><ArticleId IdType="pubmed">36483106</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer U, Pavlova D, Abbassi R, et al. Secondary sclerosing cholangitis after COVID-19 pneumonia: a report of two cases and review of the literature. Clin J Gastroenterol. 2022;15(6):1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9371366</ArticleId><ArticleId IdType="pubmed">35953614</ArticleId></ArticleIdList></Reference><Reference><Citation>Onuiri J, Fiel M. COVID cholangiopathy can occur despite mild COVID. Am J Clin Pathol. 2022;158(Supplement_1):S128&#x2013;S129. doi:10.1093/ajcp/aqac126.272</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcp/aqac126.272</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallet V, Bock K, Mandengue PD, et al. Intravenous ketamine and progressive cholangiopathy in COVID-19 patients. J Hepatol. 2021;74(5):1243&#x2013;1244. doi:10.1016/j.jhep.2021.02.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2021.02.007</ArticleId><ArticleId IdType="pmc">PMC7893247</ArticleId><ArticleId IdType="pubmed">33617925</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards K, Allison M, Ghuman S. Secondary sclerosing cholangitis in critically ill patients: a rare disease precipitated by severe SARS-CoV-2 infection. BMJ Case Rep CP. 2020;13(11):e237984. doi:10.1136/bcr-2020-237984</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2020-237984</ArticleId><ArticleId IdType="pmc">PMC7654135</ArticleId><ArticleId IdType="pubmed">33168538</ArticleId></ArticleIdList></Reference><Reference><Citation>Faruqui S, Okoli FC, Olsen SK, et al. Cholangiopathy after severe COVID-19: clinical features and prognostic implications. Am J Gastroenterol. 2021;116(7):1414&#x2013;1425. doi:10.14309/ajg.0000000000001264</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000001264</ArticleId><ArticleId IdType="pubmed">33993134</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xfc;tikofer S, Lenggenhager D, Wendel Garcia PD, et al. Secondary sclerosing cholangitis as cause of persistent jaundice in patients with severe COVID&#x2010;19. Liver Int. 2021;41(10):2404&#x2013;2417. doi:10.1111/liv.14971</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/liv.14971</ArticleId><ArticleId IdType="pmc">PMC8242687</ArticleId><ArticleId IdType="pubmed">34018314</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunyady P, Streller L, R&#xfc;ther DF, et al. Secondary sclerosing cholangitis following Coronavirus Disease 2019 (COVID-19): a Multicenter Retrospective Study. Clin Infect Dis. 2023;76(3):e179&#x2013;e187. doi:10.1093/cid/ciac565</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac565</ArticleId><ArticleId IdType="pmc">PMC9278244</ArticleId><ArticleId IdType="pubmed">35809032</ArticleId></ArticleIdList></Reference><Reference><Citation>Brevini T, Maes M, Webb GJ, et al. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature. 2023;615(7950):134&#x2013;142. doi:10.1038/s41586-022-05594-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05594-0</ArticleId><ArticleId IdType="pmc">PMC9977684</ArticleId><ArticleId IdType="pubmed">36470304</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartl L, Haslinger K, Angerer M, et al. Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID&#x2010;19 in patients with chronic liver disease. Hepatology. 2022;76(6):1563&#x2013;1575. doi:10.1002/hep.32582</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.32582</ArticleId><ArticleId IdType="pmc">PMC9347407</ArticleId><ArticleId IdType="pubmed">35596929</ArticleId></ArticleIdList></Reference><Reference><Citation>Santana MF, Guerra MT, Hundt MA, et al. Correlation between clinical and pathological findings of liver injury in 27 patients with lethal COVID&#x2010;19 infections in Brazil. Hepatol Commun. 2022;6(2):270&#x2013;280. doi:10.1002/hep4.1820</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep4.1820</ArticleId><ArticleId IdType="pmc">PMC8652714</ArticleId><ArticleId IdType="pubmed">34520633</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartlett PJ, Antony AN, Agarwal A, et al. Chronic alcohol feeding potentiates hormone&#x2010;induced calcium signalling in hepatocytes. J Physiol. 2017;595(10):3143&#x2013;3164. doi:10.1113/JP273891</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/JP273891</ArticleId><ArticleId IdType="pmc">PMC5430227</ArticleId><ArticleId IdType="pubmed">28220501</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwakiri Y, Nathanson MH. Alcohol and calcium make a potent cocktail. J Physiol. 2017;595(10):3109. doi:10.1113/JP274133</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/JP274133</ArticleId><ArticleId IdType="pmc">PMC5430223</ArticleId><ArticleId IdType="pubmed">28295353</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroepfl V, Treml B, Freund MC, Profanter C. Early detection of COVID-19 cholangiopathy using cholangioscopy&#x2014;a case report of two critically ill patients. Eur Surg. 2022;54(6):326&#x2013;330. doi:10.1007/s10353-022-00776-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10353-022-00776-6</ArticleId><ArticleId IdType="pmc">PMC9510572</ArticleId><ArticleId IdType="pubmed">36189108</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>